

REMARKS

Applicants have amended the specification paragraphs [0039] and [0093] of the application as filed such that the Par-4 polypeptides are identified by their sequence identifiers that they recite “They are 1-204, 137-221, 137-213, 137-198 and 137-195 of SEQ ID NO: 1. Support for this amendment is found in paragraphs[0040] of the application as filed, where Applicants disclose that the “Par-4 gene, first identified by the inventors (see Sells et al. 1994)” The Examiner acknowledges that a review of the document reveals that this sequence corresponds to UO5989.1. Support is also found in paragraphs [0092] and [0093] and Figures 2 and 3 where Applicants describe the preparation of the deletion mutants.. In paragraph [0092], Applicants disclose that the PCB6+Par4 plasmid was described previously in Johnstone et al. (1996) and Johstone et al. explicitly recites the 332 amino acid the sequence of the rat Par-4 protein. Paragraph [00105] recites that all references discussed above are herein incorporated by reference in their entirety and therefore the 332 amino acid Par-4 sequence of Johnstone et al. is incorporated by reference into the application.

Claims 1, 6, and 24 stand rejected under 35 U.S.C. §112, for purportedly lacking written description Applicants disagree but in view of the following remarks and the amendments to the claims Applicants request that the Examiner reconsider and withdraw the rejection.

Applicants have amended claims 1, 6 and 24 such that they refer of amino acids 1-204, 137-221, 137-213, 137-198 and 137-195 of the Par-4 protein (SEQ ID NO: 1). In paragraph [0039] of the application as filed, Applicants disclose that “one advantage of these mutants is that they define the active domain of Par-4 and localize that active domain to the 59 amino acid region between amino acids 137 and 195 of Par-4 (wild type Par-4 has 332 amino acids.)” Applicants incorporated Johnstone et al. (1996) in its entirety by reference (see paragraph [00105]) and the 332 amino acid Par-4 is disclosed in Johnstone et al., as such,

the 332 amino acid sequence is part of the application. SEQ ID NO: 1 is the sequence of the 332 Par-4 protein recited in Johnstone et al. (submitted with Applicants' IDS filed June 9, 2008.) Applicants have amended the specification paragraphs [0039] and [0093] to refer to SEQ ID NO:1 and have submitted a sequence listing reciting this sequence. Applicants have amended the specification and the claims such that they identify the position of the deletion mutants relative to the 332 Par-4 protein, SEQ ID NO: 1.


In view of the amendments to the claims and the specification, Applicants request that the Examiner reconsider and withdraw the rejection of the claims under 35 U.S.C. §112, for purportedly lacking written description.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #104072.B000118).

Respectfully submitted,

April 27, 2009


Mary Anne Schofield
Registration No. 36,669

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
MAS:xxx
dn#7693859_1